ORR 61%, ≥CR 35%; median PFS ~17 months; every-2-week dosing after 6 months maintained responses.
- 61 out of 100 people had their tumour shrink with Elranatamab.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Relapsed/refractory myeloma after ≥3 lines, BCMA-naive: elranatamab monotherapy. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (BCMA); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
123 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective response rateprimary | Elranatamab | 123 | 61% | — | — | — |
Pages like this
not linked directly; found by shared links- PairingCaution: T-cell redirectors and infections
Shares Elranatamab, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- TrialLINKER-MM1
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- TargetGPRC5D
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- Key paperMajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma
Shares Elranatamab, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- ProductTalquetamab
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- TargetBCMA
Shares Elranatamab, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- TargetCD3
Shares Elranatamab, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- ProductTeclistamab
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.